The newly approved regimen is expected to simplify administration and potentially reduce medication errors and dose-related reactions.
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.
At all time points, consistently high levels of patient satisfaction were observed (>84% reporting much or very much improved).
The FDA is expected to decide on treatments for EBV-positive posttransplant lymphoproliferative disease, breast cancer, Barth syndrome, pain, and migraine.
The single-arm, open-label APPULSE-PNH trial included 52 PNH patients who were on a stable regimen with either eculizumab or ravulizumab.
(HealthDay News) — Increased consumption of dark chocolate, but not milk chocolate, is associated with a reduced risk for type 2 diabetes (T2D), according to a study published online Dec. 4 in The BMJ ...
Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens.
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
B, Recombivax HB, or Twinrix as hepatitis B vaccination recommendations that providers can give pregnant patients.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with lupus nephritis may reduce the risk of progression to end-stage kidney disease (ESKD), according to a poster presentation ...
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
The table below is a review of notable updates that occurred in November 2024 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.